A Phase 1 interventional study of MCRcI® stem cells in Coronary Artery Disease, sponsored by Honya Medical Inc. Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Honya Medical Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Coronary Artery Disease with a site in Taiwan — 12 open to participants now, 16 under way, 2 of them phase 3. Coronary Artery Disease · Taiwan.
Among the 68 studies in Coronary Artery Disease with a site in Taiwan, this one is the 44th largest by planned enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 1, reaches primary completion later than 2 of the 15 other live ones, and was the 43rd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →12 of the 68 studies in Coronary Artery Disease with a site in Taiwan are open now. Recruiting first, the newest first:
Hexun Biosciences Co., LTD. · Sites in Taiwan
Ages 18–75
Siou-Pin Huang · Sites in Taiwan
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
CSL Behring · Sites in Taiwan, United States, Argentina and 32 more countries
Ages 18+
Seung-Jung Park · Sites in Taiwan, Hong Kong, India and 2 more countries
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 12 · Phase 4 7
First in 2004; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 172 across the 51 interventional studies, 652 across the 16 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 68 have an industry lead sponsor. The 10 most frequent:
Honya Medical Inc is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Honya Medical Inc has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
5 of the studies in Coronary Artery Disease with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07469397National Taiwan University HospitalPreliminary Exploration of Factors Affecting Complete Hemostasis and Supine Time After Removal of Femoral Arterial Sheath in ICU Patients | 2026-12-31 |
| NCT05846893B. Braun Medical Industries Sdn. Bhd.Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease | 2027-05 |
| NCT07649330Siou-Pin HuangEffects of Myofascial Release on Cardiac Patients After Median Sternotomy | 2027-05 |
| NCT07195968National Taiwan University HospitalComparative Analysis of NTG-Pd/Pa and Saline-Pd/Pa (CANS) | 2027-05-31 |
| NCT05829889Seung-Jung ParkFractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease | 2027-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 68 studies in Coronary Artery Disease with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety evaluation of Intra-Coronary Administration of MCRcI® stem cells in Patients with Diffuse Coronary Artery Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low Dose of MCRcI® stem cells.
Biological: MCRcI® stem cells
Intermediate Dose of MCRcI® stem cells.
Biological: MCRcI® stem cells
High Dose of MCRcI® stem cells.
Biological: MCRcI® stem cells
Intra-Coronary Administration of MCRcI® stem cells
Also known as: stem cells
Incidence of Treatment Emergent Adverse Events
Number of adverse events
Time frame: 6 months
Left ventricle stroke volume
Echocardiogram assessment on left ventricle stroke volume (volume of blood pumped from the left ventricle per beat (ml).
Time frame: 12 months
End diastolic volume
Echocardiogram assessment on volume of blood in the left ventricle at the end of diastolic filling (ml)
Time frame: 12 months
Left ventricular ejection fraction (LVEF)
Calculated by dividing the volume of blood pumped from the left ventricle per beat (stroke volume) by the volume of blood collected in the left ventricle at the end of diastolic filling (end-diastolic volume).
Time frame: 12 months
Severity of angina symptom using Canadian Cardiovascular Society grading.
Canadian Cardiovascular Society grading of angina pectoris is a classification system used to grade the severity of exertional angina. Scale ranges 0 \~ IV (most sever), with 0 Asymptomatic Angina, I Angina only with strenuous exertion, II Angina with moderate exertion, III Angina with mild exertion and IV Angina at rest.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Jan 2026, 1 month later.
Of 34 phase 1 interventional studies under Coronary Artery Disease, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stem Cell
Honya Medical Inc